Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;35(1-2):23-7.
doi: 10.1007/s13318-010-0004-y.

Impact of hyperlipidaemia on the orbital bone cefotaxime levels in rats

Impact of hyperlipidaemia on the orbital bone cefotaxime levels in rats

G Panitsa et al. Eur J Drug Metab Pharmacokinet. 2010 Sep.

Abstract

Facial injuries are critical conditions, leading to serious complications, such as occult facial infections. Infectious endophthalmitis occurs despite of antibiotics use during implantation of intraocular lenses and is generally resistant to antibiotic therapy. It is a crucial situation in ophthalmology, since it often induces a substantial reduction of visual acuity and in some cases the loss of the eye despite treatment. It is, therefore, important to obtain drug levels able to exert antimicrobial effect in the diseased organ. The distribution of a drug depends on the binding extent to both plasma proteins and tissues and only the free drug is capable to be transported/diffused across membranes from blood vessels into tissues, in order to achieve its effect on the target organ. Hyperlipidaemia and consequent enhanced concentration of free fatty acid can modify binding pharmacokinetics of antibiotics through antagonism for the same binding sites. Cefotaxime, the third generation cephalosporin with easy penetration in a variety of tissues and body fluids and low incidence of adverse effects, can obtain adequate concentration in blood, eye bulb, and in the orbital bones. Its levels are influenced by hyperlipidaemia with clinical impact.

PubMed Disclaimer

Similar articles

References

    1. Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R56-61 - PubMed
    1. Eur J Drug Metab Pharmacokinet. 2005 Jul-Sep;30(3):171-4 - PubMed
    1. Invest Ophthalmol Vis Sci. 1999 Aug;40(9):2010-8 - PubMed
    1. J Antimicrob Chemother. 2009 Mar;63(3):480-4 - PubMed
    1. Ophthalmic Plast Reconstr Surg. 1987;3(4):231-5 - PubMed

LinkOut - more resources